High lipoprotein(a): how to understand the result and what it may change

You open a lab report and find an unfamiliar name: lipoprotein(a), 68 mg/dL. The first thing that arrives is rarely an answer. It is three questions: is that high, can I lower it, and should I be worried?

The short answer is that Lp(a) is a mainly inherited cardiovascular risk factor. A high concentration deserves context, but it is neither a diagnosis nor a sentence. Its value is revealing one part of risk that a standard cholesterol panel may not show and helping decide whether prevention should change.

Lp(a) resembles an LDL particle. It contains one ApoB100 molecule plus an additional protein called apolipoprotein(a). Genetic and epidemiological evidence supports a causal, continuous relationship with atherosclerotic cardiovascular disease and aortic stenosis.

Because genetics explains most of the result, eating well or exercising more usually changes the number very little. That does not make healthy habits pointless. It means the practical goal is to reduce risks that can change, without chasing supplements or promises to “normalise” one marker.

At Progevita, we begin with a simple question: what decision would this result change? It may affect lipid management, prompt family testing or simply confirm that a sound plan should continue.

Evidence review note: substantively updated on 29 August 2026 using the 2022 EAS consensus, 2024 NLA and SEA statements, the 2026 ACC/AHA guideline and official trial records. This is educational content and does not replace individual clinical assessment.

What is lipoprotein(a), or Lp(a)?

Lp(a) is a lipoprotein produced mainly in the liver. Structurally, it resembles an LDL particle: it carries cholesterol and contains one apolipoprotein B100 molecule, the protein that identifies atherogenic particles. The difference is that Lp(a) also carries apolipoprotein(a), encoded by the LPA gene.

Apolipoprotein(a) varies in size from person to person. Laboratories may therefore report mass in mg/dL or molar concentration in nmol/L. There is no reliable universal conversion between these units. Always check the unit before comparing your result with a guideline or someone else's report.

The 2024 NLA update estimates that roughly one in five people has elevated Lp(a). They do not all have the same risk. Age, blood pressure, smoking, diabetes, other atherogenic particles and established cardiovascular disease can change the interpretation substantially.

What high lipoprotein(a) means

High Lp(a) does not mean you are destined to have a heart attack. It means an estimate based only on total cholesterol, LDL-C and HDL-C may miss part of the picture. Evidence supports two main clinical relationships:

• Atherosclerotic cardiovascular disease: including coronary disease, ischaemic stroke and peripheral artery disease.
• Calcific aortic stenosis: progressive narrowing of the aortic valve.

The European Atherosclerosis Society consensus combines epidemiological and genetic studies involving hundreds of thousands of people and describes a causal, continuous relationship rather than a sudden jump at one cut-off. It also corrects a common misconception: current evidence does not support Lp(a) as a risk factor for venous thrombosis.

The NLA and Spanish Society of Arteriosclerosis agree on the practical response: measure Lp(a) at least once in adults, interpret it within global risk and act early on modifiable factors. Genetics explains more than 80% of the variation in concentration.

How to read Lp(a) values without mixing units

There is no single “normal value” that divides everyone into safe or ill. Risk rises gradually. The NLA offers this framework for clinical discussion:

NLA framework	mg/dL	nmol/L	How to use it
Low risk from Lp(a)	< 30	< 75	Does not rule out other risk factors.
Intermediate risk from Lp(a)	30 to < 50	75 to < 125	Needs context, not an automatic label.
High risk from Lp(a)	≥ 50	≥ 125	May justify closer prevention according to global risk.

These ranges are not treatment targets or diagnoses. They should not be used to convert one unit into the other. A result of 60 mg/dL and one of 150 nmol/L may sit in the same broad category, but they are not mathematically equivalent.

Lp(a), LDL-C, ApoB and no-HDL-C: how they differ

Confusion begins when we call several different measurements “cholesterol.” None automatically replaces the others:

Marker	What it measures	Question it answers	Main limitation
LDL-C	Cholesterol attributed to LDL	How much cholesterol does that fraction carry?	Does not directly report particle concentration.
ApoB	Marker of total atherogenic particle concentration	What is the approximate total burden of ApoB particles?	Includes Lp(a), but does not separate it.
Lp(a)	Concentration of a particle containing ApoB and apolipoprotein(a)	Is there an additional inherited component?	Assay and unit matter.
Non-HDL-C	Total cholesterol minus HDL-C	How much non-HDL cholesterol is circulating?	Also does not measure particle concentration.

For the wider measurement map, this guide to longevity biomarkers explains why one number is rarely enough for good decisions.

When Lp(a) should be measured

Lp(a) is usually not part of a basic lipid panel. The EAS and NLA statements recommend at least one measurement in adulthood. The 2026 ACC/AHA guideline also includes Lp(a) in its evaluation of dyslipidaemias.

• Personal or family history of premature cardiovascular disease.
• Familial hypercholesterolaemia or suspicion of it.
• Known high Lp(a) in a relative.
• Cardiovascular disease or aortic stenosis not explained by usual factors.
• An uncertain preventive decision in which the result could change the plan.

When the result is elevated, cascade testing of first-degree relatives can be useful. Population distributions vary by ancestry, but ancestry cannot predict an individual's value. The person's own measurement remains the relevant information.

Routine repetition usually adds little. Retesting may make sense when there is analytical uncertainty, a condition that can alter concentration or a specific treatment whose response needs monitoring.

Symptoms of high Lp(a): why risk is usually silent

High Lp(a) usually does not hurt, cause fatigue or create a recognizable signal. It is generally found through measurement, not a particular sensation. Cardiovascular symptoms, when present, come from a specific condition and need their own assessment.

Symptoms are therefore not a useful way to decide whether to test. If you already have a high result, the next question is not “what will I feel?” but “how does this change my cardiovascular assessment?”

Can Lp(a) be lowered? What works and what does not

This is where confusion grows fastest. Lowering a laboratory number in a trial does not by itself prove that people will have fewer heart attacks or strokes. In the evidence reviewed for this article, we found no published cardiovascular outcomes result that supports recommending an Lp(a)-directed drug as a routine answer for everyone with a high value.

While that evidence matures, useful care focuses on lowering overall cardiovascular risk. The appropriate intensity depends on medical history, not one table.

Option	Effect on Lp(a)	How to interpret it
Healthy habits	Little direct effect on Lp(a)	They can improve blood pressure, metabolic health, fitness and other components of risk.
Statins	Do not lower Lp(a) and may raise it slightly	They may still provide benefit when indicated to lower LDL-C and global risk.
PCSK9 inhibitors	Modest Lp(a) reduction in trial analyses	Use depends on clinical indications and lipid goals, not isolated Lp(a).
Lipoprotein apheresis	Large but temporary reduction	A specialist option for highly selected cases; eligibility varies by country.
Pelacarsen, olpasiran, lepodisiran and other agents	Large biomarker reductions	They still need to prove event reduction and clarify who benefits enough to justify risk, burden and cost.

The FOURIER analysis included 25,096 people with established cardiovascular disease and observed a median Lp(a) reduction with evolocumab. It was a secondary analysis of a drug that changes several lipid measures, however, and does not prove that treating Lp(a) alone produces the same benefit.

The research picture changes quickly. The official registry marked Lp(a)HORIZON, the phase 3 pelacarsen trial, as completed on 16 July 2026. “Completed” does not mean that results have been published or that the treatment is approved. OCEAN(a)-Outcomes with olpasiran and ACCLAIM-Lp(a) with lepodisiran were still active, not recruiting, on this review date.

What to do if your Lp(a) is high

The useful question is not “how do I lower this number tomorrow?” but “what decisions does this result change?” This sequence can structure the conversation:

1. Confirm unit and method: mg/dL and nmol/L are not interchangeable through a simple rule. Keep the original report.
2. Place it in global risk: history, age, blood pressure, smoking, diabetes, LDL-C, non-HDL-C and ApoB provide context.
3. Review family history: an elevated concentration may justify testing first-degree relatives.
4. Agree what is modifiable: the plan may include habits, blood pressure and lipid-lowering treatment according to clinical indication.
5. Use imaging only to answer a question: a coronary calcium score or other test is not automatic after a high Lp(a) result.
6. Define follow-up: record what will be monitored and when. Repeating Lp(a) on a calendar is rarely the centre of the plan.

Quick matrix: what changes by context

Scenario	Practical reading	Reasonable clinical discussion
High Lp(a) + low ApoB + no known disease	The inherited factor is present, while part of the modifiable burden is well controlled.	Maintain control and assess the whole picture without declaring zero risk.
High Lp(a) + high ApoB/LDL-C	Two related atherogenic signals accumulate.	Review treatment intensity and goals with a clinician.
High Lp(a) + established cardiovascular disease or plaque	The result sits in a higher-risk context.	Closer follow-up and clinician-led decisions, not self-medication.

This is the logic of sensible preventive medicine: test when the information can change a decision and avoid letting one result control the whole plan.

How Progevita interprets Lp(a)

At Progevita, we do not interpret Lp(a) outside its context. We place it alongside personal and family history, blood pressure, the standard lipid panel, ApoB and any established cardiovascular disease. We add tests only when they can resolve a specific uncertainty.

The useful outcome is not an endless biomarker list. It is an explanation you can repeat in your own words and a plan with clear priorities: what to maintain, what to change, what to discuss and what is not worth chasing.

Frequently asked questions

What does high lipoprotein(a) mean?

It means your Lp(a) concentration is in a range associated with higher risk of atherosclerotic cardiovascular disease and aortic stenosis. It does not diagnose disease or predict your future on its own; it belongs in an overall cardiovascular assessment.

Does high Lp(a) cause symptoms?

A high Lp(a) concentration usually causes no symptoms. Cardiovascular symptoms come from a specific condition, not from the laboratory value itself, and need their own assessment.

Which Lp(a) levels are considered elevated?

As a clinical framework, the NLA classifies below 30 mg/dL or 75 nmol/L as low risk, 30-50 mg/dL or 75-125 nmol/L as intermediate, and 50 mg/dL or 125 nmol/L and above as high. Risk is continuous, and no universal conversion exists between units.

How often should Lp(a) be tested?

For most adults, one measurement is enough because Lp(a) is mainly genetic and usually stable. Retesting may make sense when a result is uncertain, a condition that can alter it changes, or a specific intervention requires monitoring.

Can I have high Lp(a) with normal cholesterol?

Yes. Total cholesterol or LDL-C can fall within the laboratory range while Lp(a) is elevated. The measurements are related but answer different questions and need to be interpreted within overall risk.

How can lipoprotein(a) be lowered?

Healthy habits usually change Lp(a) concentration very little, but they do reduce other important risks. Current care focuses on modifiable factors and medication chosen for individual risk. Lp(a)-directed treatments need to prove clinical benefit, not only lower the number.

Are Lp(a) and ApoB the same?

No. ApoB is a marker of total atherogenic particle concentration. Lp(a) is one specific particle that contains ApoB plus apolipoprotein(a). Measuring both can provide complementary information.

Is high Lp(a) inherited?

Largely, yes. Variants in the LPA gene explain most of the concentration. When one person has elevated Lp(a), testing first-degree relatives can identify others who need a cardiovascular risk assessment.

References

1. Kronenberg F et al. EAS consensus on Lp(a), atherosclerotic cardiovascular disease and aortic stenosis. European Heart Journal, 2022. PMCID: PMC9639807.
2. Koschinsky ML et al. NLA focused update on Lp(a) in clinical practice. Journal of Clinical Lipidology, 2024. PMID: 38565461.
3. Delgado-Lista J et al. Spanish Society of Arteriosclerosis consensus. Clínica e Investigación en Arteriosclerosis, 2024. PMID: 38599943.
4. Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. The Lancet, 2024. PMID: 39278229.
5. Blumenthal RS et al. ACC/AHA multisociety guideline on dyslipidaemia. Circulation, 2026. PMID: 41824552.
6. O'Donoghue ML et al. Lp(a), PCSK9 inhibition and cardiovascular risk in FOURIER. Circulation, 2019. PMID: 30586750.
7. Official phase 3 trial records for Lp(a)HORIZON, OCEAN(a)-Outcomes and ACCLAIM-Lp(a). ClinicalTrials.gov, accessed 29 August 2026.

This article is educational and does not replace individual medical assessment. Lp(a) interpretation depends on age, family history, other biomarkers, medication, cardiovascular imaging and clinical judgement.

Would you like to put your Lp(a) result in context? At Progevita, we can help distinguish what changes a decision from what only adds noise. Request an orientation call.